Novartis shares climbed in morning trading after the company announced positive biomarker results for del-brax in the Phase I/II FORTITUDE study. The investigational antibody oligonucleotide conjugate, being evaluated in patients with facioscapulohumeral muscular dystrophy - FSHD - met both the study's primary and key secondary endpoints in the biomarker cohort, according to the company.
Novartis highlighted reductions in KHDC1L and creatine kinase biomarker levels as the basis for the study readout. Those changes were presented by the company as evidence of robust target engagement by del-brax and an associated reduction in muscle damage among the enrolled FSHD patients.
The firm noted that del-brax remains the only investigational therapy to demonstrate disease-modifying potential for FSHD in clinical studies. The treatment also carries Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, designations that underline its regulatory status and the company's path for further discussions.
Del-brax entered the Novartis neuroscience portfolio as a result of the acquisition of Avidity Biosciences, which Novartis completed in February 2026 for $12 billion. Novartis said it plans to engage with global regulatory authorities on the Phase I/II data, indicating that the company is assessing whether the biomarker evidence might support an accelerated or conditional approval pathway.
Market conditions that day provided a modestly positive backdrop: the S&P 500 was up 0.4%, the Dow Jones rose 0.5%, and the NASDAQ increased 0.6%. Novartis's gain materially outpaced those indices, reflecting company-specific momentum.
Analysts and investors had already been paying attention to Novartis after a series of favorable pipeline readouts in recent weeks. Positive data from other late-stage programs - including Scemblix, Pluvicto, and Cosentyx - helped concentrate investor focus on the company's late-stage assets and contributed to the stock's recent advance.
Taken together, the FORTITUDE biomarker results reinforced a central element of Novartis's $12 billion neuroscience investment and created a potential regulatory catalyst through planned discussions with authorities. Those developments coincided with the stock trading at $152.43, above its prior close of $148.12 and notably higher than its 52-week low of $112.34.
What this means
- Positive biomarker outcomes for del-brax validate target engagement and show reductions in biomarkers tied to muscle damage in FSHD patients.
- The data gives Novartis a potential regulatory pathway to explore, with the company indicating it will consult global agencies about accelerated or conditional approval based on the Phase I/II findings.
- These results bolster momentum in Novartis's broader late-stage pipeline, which has seen several positive readouts recently.